4‐dihydroquinoxalin‐3‐yl)acetate and ethyl (6‐methyl‐2‐oxo‐3,4‐dihydroquinoxalin‐3‐yl)acetate (1a,b), 3‐methylquinoxalin‐2(1H)‐one (4) and 1,4‐dihydroquinoxaline‐2,3‐dione (11) were the starting precursors for nine novel quinoxaline compounds, 3a, 6, 10, 13, 15, 16, 17, 18, and 20, via adopting different nucleophilic reactions. The synthesized compounds were tested for their antiviral activity against HCV, HBV, HSV‐1
(6,7-二甲基-2-氧-3,4-二氢
喹喔啉-3-基)
乙酸乙酯和(6-甲基-2-氧-3,4-二氢
喹喔啉-3-基)
乙酸乙酯(1a,b) , 3-甲基
喹喔啉-2(1H)-one (4) 和 1,4-二氢
喹喔啉-2,3-二酮 (11) 是 9 种新型
喹喔啉化合物的起始前体, 3a, 6, 10, 13, 15, 16 , 17, 18, 和 20, 通过采用不同的亲核反应。测试合成的化合物对 HCV、HBV、HSV-1 和 HCMV 的抗病毒活性。同时,研究了它们的安全性以及它们对病毒株的选择性。阿拉巴马大学病毒学部门记录到,与
更昔洛韦 (IC50 = 0.59 μM) 相比,两种化合物,即 1a 和 20,对 HCMV 表现出高度有效的活性,其 IC50 值较低 (<0.05 μM)。